NMN vs NR vs NAD+

Last updated: October 2026

NAD+ (nicotinamide adenine dinucleotide) is the coenzyme itself, while NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are smaller vitamin B3 precursors that cells convert into it³. In the first head-to-head human trial, 14 days of NR or NMN roughly doubled whole-blood NAD+ compared with placebo, with similar results for both¹. Outside cells, NAD+ itself is broken down into these smaller precursors².

What are NAD+, NMN and NR?

Nicotinamide adenine dinucleotide (NAD+) is a pyridine nucleotide built from two nucleosides joined by a pyrophosphate group³. It is a redox cofactor in many metabolic reactions and a substrate for signaling enzymes, and its levels fall with aging and with overnutrition³. The body makes NAD+ from the amino acid tryptophan and from vitamin B3 forms, niacin and nicotinamide³.

Nicotinamide riboside (NR) is a pyridine nucleoside: nicotinamide bonded to a ribose sugar³. Nicotinamide mononucleotide (NMN) is a nucleotide: an NR molecule with a phosphate group attached³. Both occur naturally in small amounts in vegetables, meat and milk³. In other words, NR is one step from NMN, and NMN is one step from NAD+^2,3.

How does each one become NAD+ in the body?

Cells recycle NAD+ mainly through the salvage pathway, in which nicotinamide, NMN and NR are the main starting materials³. NR enters cells through equilibrative nucleoside transporters and is converted to NAD+ by the enzymes NR kinase (NRK) and NMN adenylyltransferase (NMNAT)². For NMN, the route into cells is debated: some studies show it must first be converted to NR outside the cell, while others support direct uptake². A dedicated NMN transporter, encoded by the gene Slc12a8, has been proposed³.

The gut adds a second route. Gut bacteria can convert NMN into nicotinic acid mononucleotide, which then feeds the Preiss-Handler pathway to NAD+³. A 2026 human trial with laboratory fermentation work concluded that NR and NMN are not absorbed directly into the circulation in large amounts but are slowly converted by gut microbes into nicotinic acid, a potent NAD+ precursor in whole blood¹. The same authors note that polar, charged nucleotides and nucleosides like NR and NMN are poorly absorbed when swallowed¹.

What happens to NAD+ itself outside cells?

Extracellular NAD+ is a substrate for enzymes on the outer surface of cells, including CD73, nucleotide pyrophosphatase/phosphodiesterase 1, CD38 and CD157². By breaking NAD+ down, these enzymes control how much remains outside cells, and they release nicotinamide, NR and NMN, which cells can import to rebuild NAD+ inside².

A 2019 pilot study in 11 healthy men measured what happens during a 6-hour intravenous infusion of NAD+⁷. Plasma NAD+ and its metabolites did not change for the first 2 hours, meaning infused NAD+ was rapidly and completely removed from plasma, and the metabolite pattern matched breakdown by NAD+ glycohydrolase and pyrophosphatase enzymes⁷. Urine later contained NAD+ itself and methylnicotinamide⁷. The study was funded in part by an NAD+ research company, and one author directs a clinic that offers intravenous NAD+⁷.

How do NMN and NR compare in human studies?

Before 2026, no trial had compared them directly¹. The first head-to-head trial, published in 2026, compared NR, NMN, nicotinamide and placebo for 14 days in 65 healthy adults, using a randomized, open-label design¹. NR and NMN each raised baseline whole-blood NAD+ about twofold compared with placebo, by 49.4 and 43.1 micromoles per liter respectively, while nicotinamide did not¹. All three were well tolerated, and the trial's researchers were employed by a food and nutrition company¹.

Earlier trials studied one precursor at a time. The first human pharmacokinetic trial of NR found that single servings produced increases in the blood NAD+ metabolome that grew with the amount given, and identified nicotinic acid adenine dinucleotide (NAAD) as a sensitive marker of NAD+ repletion⁴. A 2 by 6-week randomized crossover trial in healthy middle-aged and older adults found NR well tolerated and raised NAD+ in blood mononuclear cells by about 60% versus placebo⁵. For NMN, a single-arm study in 10 healthy Japanese men found that single servings caused no significant clinical symptoms or changes in heart rate, blood pressure, oxygen saturation or body temperature, while NMN metabolites in plasma rose with the amount given⁶.

Which is better, NMN or NAD+?

On the research so far, the precursors have the stronger evidence for raising NAD+ measured in blood. Controlled trials show NR and NMN raise blood NAD+^1,5, while NAD+ outside cells is broken down into precursors before cells use it², and infused NAD+ was cleared from plasma within the first 2 hours⁷. Between NR and NMN, the one direct comparison found no meaningful difference in the rise in whole-blood NAD+¹.

A higher NAD+ reading is not the same as a proven health effect^1,5. The head-to-head trial raised NAD+ above normal values in healthy people, and its authors state that the consequences of restoring NAD+ in people with disease still need study¹. The NR crossover trial reported only initial insight into physiological function and called for further trials on blood pressure and arterial stiffness⁵. A 2023 review adds that the effects of long-term and high-intake use remain to be determined³.